Expert Interview
Discussing Denali Therapeutics’ investigational brain-penetrant enzyme therapy, tividenofusp alfa, for mucopolysaccharidosis type II (Hunter syndrome), and its potential to address both neurologic and peripheral disease manifestations
Ticker(s): DNLIPediatric geneticist, metabolic disease specialist, or pediatric neurologist with experience managing patients with Hunter syndrome / MPS II and familiarity with enzyme replacement therapy and CNS disease progression.
What is your interpretation of the clinical data for tividenofusp alfa, particularly the reported effects on CNS biomarkers, peripheral biomarkers, and clinical measures such as cognition, adaptive behavior, hearing, or organ involvement?
Added By: sara_adminHow clinically meaningful do you believe a brain-penetrant enzyme replacement therapy could be for patients with MPS II, especially if initiated before advanced neurologic impairment?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
